LARA SHIGIHARA: Open Payments
NPI 1427660992 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,690 in 84 payments from 15 companies in 2025. Trend: 2023 $1,489 · 2024 $1,897 · 2025 $1,690
Food & beverage: $1,680Education: $10
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $425 |
| AstraZeneca Pharmaceuticals LP | 14 | $306 |
| Amgen Inc. | 8 | $178 |
| PFIZER INC. | 9 | $163 |
| Novo Nordisk Inc | 7 | $147 |
| GlaxoSmithKline, LLC. | 5 | $114 |
| Otsuka America Pharmaceutical, Inc. | 4 | $92 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $56 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $47 |
| Lilly USA, LLC | 2 | $43 |
Products named: VRAYLAR, BREZTRI, NURTEC ODT, OTEZLA, FARXIGA, REXULTI, Wegovy, SHINGRIX.
Industry payments across NV — which companies pay providers there.
